Agilent Technologies (NYSE:A) Stock Price Expected to Rise, Citigroup Analyst Says

Agilent Technologies (NYSE:A) had its price target raised by equities researchers at Citigroup to $165.00 in a research report issued on Thursday, Stock Target Advisor reports. The firm currently has a “buy” rating on the medical research company’s stock. Citigroup’s price target indicates a potential upside of 22.67% from the stock’s current price.

A has been the topic of several other reports. Barclays lowered their target price on Agilent Technologies from $145.00 to $135.00 and set an “underweight” rating on the stock in a research report on Wednesday, November 27th. JPMorgan Chase & Co. cut their price objective on Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a research note on Tuesday, November 26th. TD Cowen raised their target price on shares of Agilent Technologies from $153.00 to $160.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. StockNews.com lowered shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, November 26th. Finally, Wells Fargo & Company decreased their price objective on shares of Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating on the stock in a research report on Monday, December 9th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $143.62.

Agilent Technologies Price Performance

Shares of NYSE:A opened at $134.51 on Thursday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.58 and a current ratio of 2.09. The firm has a market cap of $38.65 billion, a price-to-earnings ratio of 30.43, a price-to-earnings-growth ratio of 4.48 and a beta of 1.07. The business has a 50-day simple moving average of $135.85 and a two-hundred day simple moving average of $136.44. Agilent Technologies has a fifty-two week low of $124.16 and a fifty-two week high of $155.35.

Agilent Technologies (NYSE:A) last posted its earnings results on Monday, November 25th. The medical research company reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.41 by $0.05. The business had revenue of $1.70 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a net margin of 19.80% and a return on equity of 25.43%. The firm’s revenue was up .8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.38 EPS. On average, analysts expect that Agilent Technologies will post 5.56 earnings per share for the current year.

Insider Buying and Selling at Agilent Technologies

In other news, SVP Dominique Grau sold 9,990 shares of the company’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $145.00, for a total value of $1,448,550.00. Following the transaction, the senior vice president now directly owns 40,011 shares in the company, valued at approximately $5,801,595. This represents a 19.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.33% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Crewe Advisors LLC increased its position in Agilent Technologies by 114.8% during the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 101 shares during the period. Livelsberger Financial Advisory bought a new position in shares of Agilent Technologies during the third quarter valued at approximately $28,000. Ridgewood Investments LLC purchased a new position in Agilent Technologies during the second quarter valued at approximately $29,000. Ashton Thomas Securities LLC bought a new position in Agilent Technologies in the third quarter worth approximately $31,000. Finally, Fortitude Family Office LLC raised its stake in Agilent Technologies by 68.3% in the third quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company’s stock worth $35,000 after buying an additional 95 shares in the last quarter. 87.42% of the stock is currently owned by hedge funds and other institutional investors.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.